Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Suprafascial Vancomycin Powder for Prevention of Surgical Site Infections After Spinal Fusion
NCT04017468Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Oct 2019
- Primary completion
- Jun 2026
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of vancomycin in surgical site infection (SSI) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Rate of superficial and deep Surgical Site Infections at 90 days. Started Oct 2019; status: completed.
02
Drugs
vancomycin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT04017468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017468.